From the publishers of JADPRO

DLBCL Resource Center

Advertisement
FROM THE EDITOR

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com

Katherine L. Byar, MSN, APN, BC, BMTCN®️®️®️
Oncology/ Hematology Nurse Practitioner
Fred & Pamela Buffett Cancer Center
Nebraska Medicine
Omaha, Nebraska

News & Literature Highlights

Current Oncology

Ibrutinib plus RCHOP versus RCHOP only in young patients with activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL): A cost-effectiveness analysis

British Journal of Haematology

The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline

Future Oncology

Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation

2023 American Society of Hematology Annual Meeting Abstract

Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study

2023 American Society of Hematology Annual Meeting Abstract

Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5

2023 American Society of Hematology Annual Meeting Abstract

Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume

HemaSphere

Clonal relationship and mutation analysis in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with diffuse large B-cell lymphoma

International Journal of Cancer

Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study

Frontiers in Oncology

Hepatitis B virus and B-cell lymphoma: Evidence, unmet need, clinical impact, and opportunities

Clinical Lymphoma, Myeloma, and Leukemia

ABCL-647 The outcome of tisagenlecleucel (tisa-cel) CD-19 CAR-T cell therapy in NHL relapsed/refractory beyond second line of therapy, single-center data

Advertisement
Advertisement